1. Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
- Author
-
Characiejus D, Pasukoniene V, Jacobs JJ, Eidukevicius R, Jankevicius F, Dobrovolskiene N, Mauricas M, Van Moorselaar RJ, and Den Otter W
- Subjects
- Administration, Intravesical, Adult, Aged, Aged, 80 and over, CD57 Antigens biosynthesis, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Urinary Bladder Neoplasms blood, Urinary Bladder Neoplasms surgery, CD57 Antigens immunology, CD8-Positive T-Lymphocytes immunology, Interleukin-2 administration & dosage, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms immunology
- Abstract
Background: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval., Patients and Methods: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9 × 10(6) IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8(high)CD57(+) lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment., Results: The multivariate analysis showed that CD8(high)CD57(+) lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients., Conclusion: Peripheral blood CD8(high)CD57(+) lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.
- Published
- 2011